Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cannabinoid-derived inhalation capsule PPP011

A capsule-based inhalation formulation containing a blend of synthetic cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), with potential anti-cachexia and analgesic activities. Upon inhalation of PPP011, the CBDs target and bind to the cannabinoid (CB) receptors. This may increase appetite, food intake and may relief pain. CB receptors, belonging to the G protein-coupled receptor superfamily, are involved in the regulation of appetite, food intake, body weight and nociception.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	synthetic CBD PPP011
Foreign brand name:	Caumz Caumz
Code name:	PPP 011 PPP-011 PPP011

cannabinoid-derived inhalation capsule PPP011

Search NCI's Drug Dictionary